143 related articles for article (PubMed ID: 36549169)
1. Survival and prognostic factors in oligometastatic breast cancer.
van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
[TBL] [Abstract][Full Text] [Related]
2. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Steenbruggen TG; Schaapveld M; Horlings HM; Sanders J; Hogewoning SJ; Lips EH; Vrancken Peeters MT; Kok NF; Wiersma T; Esserman L; van 't Veer LJ; Linn SC; Siesling S; Sonke GS
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977227
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study.
Xie Y; Ma J; Xia X; Zheng H; Gou Q
Cancer Control; 2022; 29():10732748221130568. PubMed ID: 36164749
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.
Mimoto R; Kobayashi T; Imawari Y; Kamio M; Kato K; Nogi H; Toriumi Y; Hirooka S; Uchida K; Takeyama H
Breast Cancer Res Treat; 2014 Sep; 147(2):317-24. PubMed ID: 25156580
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
Steenbruggen TG; Wolf DM; Thijssen B; Sanders J; Cornelissen S; Salgado R; Mittempergher L; Bhaskaran R; Broeks A; Lips EH; Siesling S; Sonke GS; Horlings HM; van 't Veer LJ
JCO Precis Oncol; 2023 Sep; 7():e2200670. PubMed ID: 37738542
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution.
Lacaze JL; Chira C; Glemarec G; Monselet N; Cassou-Mounat T; De Maio E; Jouve E; Massabeau C; Brac de la Perrière C; Selmes G; Ung M; Nicolai V; Cabarrou B; Dalenc F
Breast Cancer Res Treat; 2023 Apr; 198(3):463-474. PubMed ID: 36790573
[TBL] [Abstract][Full Text] [Related]
11. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
12. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China.
Lan B; Abudureheiyimu N; Zhang J; Wang C; Jiang S; Wang J; Ma F; Luo Y; Chen S; Xu B; Fan Y
Int J Cancer; 2020 Dec; 147(11):3199-3205. PubMed ID: 32535918
[TBL] [Abstract][Full Text] [Related]
14. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
15. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
17. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
Imoto S; Wang K; Bi XW; Liu G; Im YH; Im SA; Sim SH; Ueno T; Futamura M; Toi M; Fujiwara Y; Ahn SG; Lee JE; Park YH; Takao S; Oba MS; Kitagawa Y; Nishiyama M
Breast Cancer; 2023 May; 30(3):412-423. PubMed ID: 36689066
[TBL] [Abstract][Full Text] [Related]
18. Oligometastatic Breast Cancer: How to Manage It?
Barberi V; Pietragalla A; Franceschini G; Marazzi F; Paris I; Cognetti F; Masetti R; Scambia G; Fabi A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207648
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
20. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
